Memantine HCl

5 Drugs classified under this active ingredient

NMDA Antagonist. Memantine HCl 10 mg.
TABS: 56. Max: 20 mg dly. Titrat. for
maint. dose by 5 mg/wk for first 3 wks:
1st wk: 5 mg dly (1/2 tab); 2nd wk: mg
1 x dly; 3rd wk: 15 mg 1 x dly.; 4th
wk: Cont. with maint. dose: 20 mg 1 x
dly. See lit.
Tmt. of pts. with moder.- sev. Alzheimer’s
dis.
C/I: Hypersens.

NMDA Antagonist. Memantine HCl 20 mg.
TABS: 28, 56. Max: 20 mg dly. Titrat. for
maint. dose by 5 mg/wk for first 3 wks:
1st wk: 5 mg dly (1/2 tab); 2nd wk: mg
1 x dly; 3rd wk: 15 mg 1 x dly.; 4th
wk: Cont. with maint. dose: 20 mg 1 x
dly. See lit.
Tmt. of pts. with moder.- sev. Alzheimer’s
dis.
C/I: Hypersens.

NMDA Antagonist. Memantine HCl 10 mg/g.
ORAL SOL.: 50 g x 5 mg pump
actuation. Recommend. maint. dose:
20 mg (4 pump actuats.) dly achieved
by upward titrat. of 5 mg/wk over 1st 3
wks as follows: 1st wk: 1 pump actuat.
1 x dly, 2nd wk: 2 pump actuats. 1 x
dly; 3rd wk: 3 pump actuats. 1 x dly;
4th week on: Max 4 pump actuats. 1 x
dly. Not recommend. child under 18
yrs. See lit.
Tmt. of pts. with moder.- sev. Alzheimer’s
dis.
C/I: Hypersens.

NMDA Antagonist. Memantine HCl 10 mg, 20 mg.
TABS: 28, 56. Max. dly dose: 20 mg.
Achieved by titrat. of 5 mg/wk over 1st 3
wks. as foll: Week 1: 5 mg dly (1/2 tab in
morn.); week 2: 10 mg 1 x dly; week 3: 15
mg 1 x dly; week 4 and follow:
recommend. maint. dose: 20 mg 1 x dly.
See lit.
Mod.-severe to severe Alzheimer’s dis.
C/I: Hypersens.

NMDA Antagonist. Memantine HCl 10 mg, 20 mg.
F.C. TABS.: 28,56. Adult. & elderly - 20 mg/d. To reduce the risk for side effects: 1st wk.: 5 mg/d. 2^nd wk.: 10 mg/d. 3^rd wk.: 15 mg/d. 4^th Week and beyond: 20/d. The init. dose 5mg/d. during the 1^st week. On the 2^nd wk., 1 tab. (10mg)/d. On the 2rd wk., 1/2 tab. (5mg)/d. From the 4th wk. and beyond, 20 mg/d. See lit.
Treatment of patients with moderate to severe Alzheimer’s disease.
C/I: Hypersens.